Proven Intelligence in Regulatory CMC for Advanced Therapies.

Executive Summary

For developers of cell-based Advanced Therapy Medicinal Products (ATMPs), the Chemistry, Manufacturing, and Controls (CMC) section of an Investigational Medicinal Product Dossier (IMPD) is a defining component for MHRA review. Cell therapies such as CAR-T, CAR-NK, or engineered stem cells introduce significant complexity related to product variability and manufacturing control. A successful submission requires a CMC strategy that prospectively addresses identity, purity, potency, and process consistency with robust analytical data.

Defining the Manufacturing Process for Cellular ATMPs

The manufacturing process for autologous or allogeneic cell therapies is the foundation of the CMC data package. Every step, from starting material collection to final cryopreservation, must be meticulously defined and controlled.

Key areas of focus for MHRA submissions include:

• Starting and Raw Materials: Comprehensive qualification of all materials, including apheresis products, cell culture media, cytokines, and viral vectors used for transduction. Full traceability is a primary regulatory expectation.

• Process Control: Identification of process parameters that impact the final product’s quality attributes. This includes transduction efficiency, cell expansion kinetics, and harvest procedures.

• Chain of Custody: For autologous therapies, demonstrating an unbroken and verifiable chain of identity and custody from patient to manufacturing and back to the clinic is a regulatory requirement.

Our >100,000 sq ft facilities provide the infrastructure for developing and executing these complex manufacturing processes under GxP conditions.

The Central Role of Analytics in Product Characterization

A well-defined analytical strategy is necessary to characterize the cell therapy product and ensure lot-to-lot consistency. The MHRA expects a suite of validated, phase-appropriate assays that provide a comprehensive profile of the ATMP. This includes assays for identity (e.g., CAR expression via flow cytometry), purity (measuring residual process components), and strength (cell count and viability).

Potency assays present a particular challenge. These assays must reflect the product’s intended biological mechanism of action, such as target cell killing for a CAR-T product. Developing a reproducible and meaningful potency assay is a frequent topic of regulatory interaction. The principle of rigorous characterization extends across all advanced modalities. Understanding unexpected biological interactions, such as toxicities identified in certain viral vector systems (PMID: 38327046), underscores the requirement for a comprehensive analytical package to define the quality and safety profile for any ATMP, including cell-based constructs.